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We aimed to obtain an in-depth understanding on recent antimicrobial resistance trends
and molecular epidemiology trends of S. aureus bacteraemia (SAB).
Methods
Thirteen academic centres in South Africa were included from June 2010 until July 2012. S.
aureus susceptibility testing was performed on the MicroScanWalkaway. Real-time PCR
using the LightCycler 480 II was done formecA and nuc. SCCmec and spa-typing were
finalized with conventional PCR. We selected one isolate per common spa type per prov-
ince for multilocus sequence typing (MLST).
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Results
S. aureus from 2709 patients were included, and 1231 (46%) were resistant to methicillin,
with a significant decline over the three-year period (p-value = 0.003). Geographical distri-
bution of MRSA was significantly higher in Gauteng compared to the other provinces
(P<0.001). Children <5 years were significantly associated with MRSA with higher rates
compared to all other age groups (P = 0.01). The most prevalent SCCmec type was
SCCmec type III (531 [41%]) followed by type IV (402 [31%]). Spa-typing discovered 47 dif-
ferent spa-types. The five (87%) most common spa-types were t037, t1257, t045, t064 and
t012. Based on MLST, the commonest was ST612 clonal complex (CC8) (n = 7) followed by
ST5 (CC5) (n = 4), ST36 (CC30) (n = 4) and ST239 (CC8) (n = 3).
Conclusions
MRSA rate is high in South Africa. Majority of the isolates were classified as SCCmec type
III (41%) and type IV (31%), which are typically associated with hospital and community-
acquired infections, respectively. Overall, this study reveals the presence of a variety of hos-
pital-acquired MRSA clones in South Africa dominance of few clones, spa 037 and 1257.
Monitoring trends in resistance and molecular typing is recommended to detect changing
epidemiological trends in AMR patterns of SAB.
Introduction
The prevalence of antimicrobial resistant bacteria from healthcare-associated infections
(HAIs) is increasing [1]. Laboratory-based surveillance for antimicrobial resistance (AMR)
generates reliable data on the occurrence of AMR in different geographical regions and pro-
vides a platform for future interventions. Amongst pathogens causing hospital infections,
Gram-positive cocci have become predominant over the past few decades, globally [2].
The increasing numbers of antimicrobial resistant Gram-positive isolates from hospital set-
tings is demonstrated in the national surveillance reports from high, middle and low income
countries [3,4]. However, South Africa has a complex healthcare system; therefore, a national
surveillance report of this nature was not available.
Staphylococcus aureus is one of the most common Gram-positive pathogens isolated from
humans [5]. Importantly, in the last two decades there have been increased reports of methicil-
lin-resistant S. aureus (MRSA) isolates from the community which were previously only cul-
tured from hospitalized patients.
The prevalence of MRSA in both hospital and community settings varies depending on geo-
graphical diversity setting [6]. The changing epidemiology of MRSA is due to the co-existence
of healthcare-associated MRSA (HA-MRSA) and community-associated MRSA (CA-MRSA)
infections. However, the epidemiology is more complex since some community onset MRSA
infections are caused by hospital-associated strains as a result of outpatient management of
MRSA infections with so called feral, HA-MRSA strains [5]. This epidemiology of S. aureus
has not been ascertained in the South African setting. S. aureus bacteraemias (SAB) are difficult
to treat and is associated with 29–63% mortality [7,8]. The emergence of new CA-MRSA
strains in the community has huge implications on patient treatment [5]. These strains have
been distinguished by molecular characterization of the staphylococcal cassette chromosome
mec (SCCmec) with HA-MRSA carrying a large SCCmec type I-III and the CA-MRSA strains
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carrying the smaller SCCmec elements IV-V [5]. A number of virulence factors have been iden-
tified in these strains such as the Panton-Valentine leukocidin (PVL). Other molecular typing
methods such as spa-typing and multilocusmulti-locus sequence typing (MLST) are useful in
investigating evolutionary relationships amongst isolates and enable study of routes of trans-
mission to assess the source of infection. Geographically, these isolates are diverse and typing
methods are used to confirm common strains in specific regions. It is important to detect and
understand the molecular characteristics of MRSA isolates as this may impact on patient’s
treatment and antibiotic choice.
Aims
We aimed to determine the antimicrobial resistance trends and molecular epidemiology of
S. aureus bacteraemia (SAB), in hospitalised South African patients through national labora-
tory-based sentinel site surveillance over a three year period.
Methods
AMR Surveillance is a subset of the GERMS-SA (Group for Enteric, Respiratory and Meningeal
Surveillance in South Africa) programme which collects isolates for phenotypic and molecular
analysis from sentinel sites.
Patient selection
S. aureus isolated from blood cultures between June 2010 and July 2012 were received from
thirteen academic centres serving the public healthcare sector in SA. The sites represented 4
regions: Gauteng [GP], KwaZulu-Natal [KZN], Free State [FS], and Western Cape [WC]
provinces.
Case definitions
We defined a case of S. aureus bacteraemia (SAB) as S. aureus isolated from a blood culture. A
new case of SAB in the same patient was reported if the organism was isolated 21 or more days
from the date of the first positive blood culture. The term methicillin-resistant Staphylococcus
aureus (MRSA) defined all oxacillin-resistant isolates.
Phenotypic methods
S. aureus isolates were submitted on Dorset transport media (Department of Media Production
at NHLS). Organism identification was confirmed using the Vitek 2 GP card (Biomerieux,
France). Susceptibility testing was performed on the MicroScan Walkaway system (Siemens
Healthcare Diagnostics, USA) using Positive MIC Panel Type 33, with breakpoint ranges from
resistant to susceptible. Categorical results and the susceptibility profiles of each antimicrobial
agent tested were based on the Clinical Laboratory Standards Institute (CLSI) interpretative
criteria [9]; Breakpoint tables for interpretation of MICs and zone diameters by EUCAST [10]
and/or the MicroScan recommendations. The MIC50 and MIC90 (minimum inhibitory concen-
trations needed to inhibit the growth of 50% and 90% of organisms, respectively) were
determined.
Molecular methods
DNA Extraction. Half a loop of bacterial culture from purity plates was re-suspended in
400μl TE buffer. This was vortexed briefly and heated at 95°C for 25 min to allow bacterial cell
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lysis to release the DNA. Centrifugation followed at 12000rpm for 3 min to pellet the cellular
debris. The supernatant was then aliquoted and stored at -70°C for further use.
Polymerase Chain Reaction (PCR) screening formecA andmecC genes in MRSA iso-
lates. The LightCycler 480 II (Roche Applied Science) instrument was used for the real-time
PCR ofmecA and nuc which were amplified in a multiplex assay using the LightCycler 480
Probes Master kit (Roche Diagnostics, IN, USA) with previously published primers and probes
[11]. The G-Storm (Somerton Biotechnology Centre, UK) thermal cycler was used for the con-
ventional PCR ofmecC using the Qiagen Multiplex PCR kit (Qiagen, Germany) with previ-
ously published primers [12].
SCCmec typing. AllmecA-positive MRSA isolates were typed by multiplex PCR using the
Qiagen Multiplex PCR kit (Qiagen, Germany) and previously published primers [13].
Spa-typing. Spa-typing was performed on 569 MRSA isolates. The spa gene was amplified
using previously published primers [14] and the Amplitaq Gold DNA Polymerase kit (Applied
Biosystems, CA, USA). Purified PCR products (Qiagen Purification kit; Qiagen, Germany)
were sequenced (Inqaba Biotech, South Africa). Sequences were assembled using CLC Bio
main workbench (Qiagen, Germany) and analysed using the Ridom StaphType™ software
(Ridom GmbH, Würzburg, Germany).
Multilocus sequence typing (MLST). One isolate per common spa types per province
were selected for MLST. Primers [15] amplifying seven reference genes were used. Amplifica-
tion was done using the Amplitaq Gold DNA Polymerase kit (Applied Biosystems, CA, USA).
Purified PCR products were sequenced (Inqaba Biotech, South Africa). Sequences were assem-
bled using CLC Bio main workbench (Qiagen, Germany) and analysed using the online data-
base (http://saureus.mlst.net/).
Ethics
Approval for this retrospective study was obtained from the Human Research Ethics Commit-
tee (Medical) (HREC), University of Witwatersrand, Johannesburg (protocol number
M10464). All patients information were anonymized preceding the analysis.
Statistical analysis
We used the Pearson’s chi-squared test or Fisher’s exact test as applicable to calculate P-values
for analysis of trends in antibiotic susceptibility. A P-value<0.05 was deemed statistically
significant.
Results
A total of 2709 S. aureus isolates from patients with bacteraemia were included during the
study period. The majority of patients were adult males (51%). A higher prevalence of SAB was
found in young patients (0–9 yearage group) (33%) in Fig 1. The highest numbers of isolates
were from patients in Gauteng, 1612 (59.5%).
Methicillin resistance was detected in 1231 (46%) isolates with the MIC method (Fig 2) and
confirmed withmecA in 1160 (43%) isolates (3% discrepant results). During the study period,
MRSA rates declined significantly from 53% in 2010 to 40% in 2012 (P =<0.001) (Fig 3).
Resistance to macrolides, aminoglycosides, tetracycline, rifampin and mupirocin remained
comparable while ciprofloxacin and trimethoprim-sufamethoxazole resistance significantly
declined over the surveillance period (P = 0.003 and 0.001 respectively) (Fig 3). MIC50 and
MIC90 remained stable for all antimicrobials tested with no changes over the study period
(Table 1).
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MRSA was resistant to more of the other classes of antimicrobial agents compared to MSSA
(Table 2). Isolates remained fully susceptible to glycopeptides, daptomycin, linezolid, quinu-
pristin-dalfopristin throughout the study period (Fig 3). From 988 SCCmec types (II-IV), 75%
were clindamycin resistant and 59% of these isolates were healthcare associated SCCmec types
II and III (Fig 4).
Fig 1. Age distribution of 2711 patients with SA bacteraemia from June 2010—July 2012.
doi:10.1371/journal.pone.0145429.g001
Fig 2. Number of MRSA isolates from four provinces.
doi:10.1371/journal.pone.0145429.g002
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PCR Screening formecA andmecC in MRSA isolates
All genotypically confirmed MRSA isolates harboured both themecA and the species specific
nuc genes (except 2 nuc-negative isolates). No isolate harboured themecC gene.
SCCmec typing. MRSA isolates (1236) were typed to identify the prevalentmec element
types. Distribution of SCCmec types across provinces differed as the numbers of isolates
received from each province varied. SCCmec types III and IV were predominantly isolated in
Gauteng and the emergence of type V was noted in 2012. Type V was identified in KwaZulu
Natal in 2011. SCCmec type VI was predominantly isolated in Western Cape in 2011. Type IV
was found in all provinces. Overall the most prevalent SCCmec type for all three years was
SCCmec type III (531 [41%]) followed by types IV (402 [31%]), II (64 [5%]), VI (4 [0.3%]) and
V (2 [0.2%]) (Fig 5). SCCmec type I was not observed but unknown typing patterns were iden-
tified (185 [12%]). Three isolates produced no amplicons. The majority of isolates representing
SCCmec types III and IV were from Gauteng [482 (37%) and 212 (16%), respectively] followed
by the Western Cape [31 (2%) and 83 (6%), respectively] and KwaZulu-Natal [5 (0.4%] and 97
(8%) respectively] (Fig 6). Of the 185 unknown typing patterns observed, the majority (113,
61%) was from the Western Cape.
Spa-typing. Spa-typing of 569 of the isolates revealed 47 different spa-types, nine of which
were novel and have not as yet been assigned.
The five most common spa-types were t037 (n = 274), t1257 (n = 120), t045 (n = 42), t064
(n = 34) and t012 (n = 22) which accounted for 87% of the isolates tested. Spa-type was t037
-and t1257 related to hospital- and community- associated infections respectively (Figs 6 and
7). Both were distributed in all four provinces except KZN, where spa-type t037 was not found
(Fig 6).
The spa-types clustered into 4 spa clonal complexes (spa-CC) using the Based Upon Repeat
Pattern (BURP) algorithm at a cost setting of4 and excluding spa-types with 5 or fewer
Fig 3. Antimicrobial susceptibility of 2709 SA isolates.
doi:10.1371/journal.pone.0145429.g003
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repeats (Ridom StaphType™ software, Ridom GmbH, Würzburg, Germany). Spa-CC-037/012
(54% of all spa-types) was the largest clonal complex followed by spa-CC-064 (32% of all spa-
types) and spa-CC-045 (7.7% of all spa-types). Spa-CC-064 contained isolates displaying pre-
dominantly the SCCmec type IV element. Spa-CC-037 contained isolates that displayed
SCCmec types II, III, IV and unknown typing patterns with a predominance of type III (Fig 3).
These clonal complexes were widespread in South Africa. Spa-CC-064 and spa-CC-037 were
identified in Gauteng, Western Cape, KwaZulu-Natal and the Free State provinces.
Multilocus sequence typing (MLST). One isolate belonging to each of the most common
spa-types per province was selected for MLST. The commonest ST was ST612 of clonal com-
plex (CC8) (n = 7) followed by ST5 (CC5) (n = 4), ST36 (CC30) (n = 4) and ST239 (CC8)
(n = 3). One isolate with spa-type t1257 produced a new pta_ allele; therefore a ST could not be
assigned. The isolates corresponding SCCmec types, spa-types and ST can be seen in Table 3.
Discussion
This study highlights the changing pattern of S. aureus resistance to oxacillin (MRSA) and
other agents using laboratory based sentinel site surveillance data that impacts on patient man-
agement. Gauteng province contributed to the majority of isolates (59.5%) and the highest
prevalence of MRSA (53%), most likely as it is the most populated province with the largest
academic centres. The high percentage of bacteraemic SA isolates that were resistant to oxacil-
lin (46%) is of serious public health concern.















MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 S R
Gentamicin 4 >8 4 >8 4 >8 4 16
Tobramycin 8 >8 4 >8 4 >8 4 16
Oxacillin 2 >2 2 >2 2 >2 2 4
Erythromycin 0.5 >4 0.5 >4 0.5 >4 0.5 8
Azithromycin 2 4 2 4 2 4 2 8
Clindamycin 0.25 0.5 0.25 0.5 0.25 0.5 0.5 4
Daptomycin 1 1 1 1 1 1 1 -
Ciproﬂoxacin 1 >2 1 >2 1 >2 1 4
Tetracycline 4 >8 4 >8 4 >8 4 16
Rifampin 1 >2 1 >2 1 >2 1 4
Linezolid 2 2 2 2 2 2 4 8
Trimethoprim/sulfamethoxazole 2/38 >4/76 2/38 >4/76 2/38 >4/76 2/38 4/76
Mupirocin 4 256 4 256 4 256 4 256
Teicoplanin 1 1 1 1 1 1 8 32
Vancomycin 1 1 1 1 1 1 2 16
Quinupristin-dalfopristin 1 1 1 1 1 1 1 4
Fosfomycin* 32 32 32 32 32 32 32 32
Fusidic acid** 2 2 2 2 2 2 2 32
* Based on EUCAST
**Based on Comite de Antibiogramme de la Societe Francaise de Microbiologie (CA-SFM, 2008).
doi:10.1371/journal.pone.0145429.t001
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The rate of MRSA from previous studies varies. A systematic review of 263 articles identified
on PubMed for the epidemiology of MRSA in Africa showed percentages of MRSA from 12 in
Tunisia to 82 in Egypt. Low prevalence of MRSA was 3.7% for all specimens and 6.5% in blood
from two private hospitals in Kenya [4,16]. However in 1997, a Kenyan national referral hospi-
tal reported a MRSA prevalence of 40%. This significant decrease in MRSA was possibly
explained as a result of changing in diagnostic methods or true decline which could be
answered by continuous monitoring of AST. During our study period, we identified a decline
in the MRSA rate from 53% in 2010 to 40% in 2012 with the exception of Gauteng and a
decline in resistance to aminoglycosides and fluoroquinolones which may be linked to the
same resistance element. MRSA rate was the lowest in the WC province (37%). This might be
explained by geographic variation in the prevalence of organisms in the hospitals across the
country. In addition the implementation of the infection prevention and control bundles
approach, comprising contact precautions, hand hygiene and a change in institutional practices
antibiotic prescription culture advocated both nationally and internationally may have contrib-
uted to the possible decline in MRSA rate.
In our study, resistance to clindamycin (40%) was higher than that described by Marais in
2009 [17]. Most of clindamycin resistant isolates were MRSA, SCCmec III and IV.
Resistance to mupirocin using EUCAST breakpoints (>256mg/L) ranged from 8% to 5%,
which was similar to the 2009 report [15].
Rare cases of reduced susceptibility to glycopeptides were reported in MRSA isolates [5]; in
this study all isolates were susceptible.
All strains carried themecA gene, while themecC was absent. Also,mecC is associated with
specific sequence types not prevalent in South Africa [18]. The majority of isolates were
Table 2. Comparison of MRSA andMSSA in susceptibility to antimicrobial agents for 2709 S. aureus isolates.
Antimicrobial agents MSSA MRSA P-VALUE
Susceptible (%) Non-susceptible (%) Susceptible (%) Non-susceptible (%)
Amikacin 19.7 80.34 6.6 93.4 0.004
/Augmentin 98.5 1.5 0.1 99.9 <0.001
Ampicillin 10.5 89.5 0 100 <0.001
Azithromycin 89.5 10.5 16.3 83.7 <0.001
Cefepime 99.3 0.7 0.1 99.9 <0.001
Cefoxitin 99.8 0.2 5.1 94.9 <0.001
Cefuroxime 98.9 1.1 0.1 99.9 <0.001
Ciproﬂoxacin 94 6 15.2 84.8 <0.001
Clindamycin 92.9 7.1 24.8 75.2 <0.001
Erythromycin 89.4 10.6 16.2 83.8 <0.001
Fosfomycin 99.6 0.4 99.6 0.4 0.818
Fusidic Acid 99.4 0.6 98.1 1.9 0.002
Gentamicin 83.8 16.2 8.3 91.7 <0.001
Linezolid 100 0 100 0 N/A
Mupirocin 97.8 2.2 82.6 17.4 <0.001
Rifampin 94.8 5.2 57.4 42.6 <0.001
Teicoplanin 100 0 100 0 N/A
Vancomycin 100 0 100 0 N/A
Tetracycline 83.8 16.2 16.6 83.4 <0.001
Tobramycin 87.2 12.8 6.5 93.5 <0.001
Moxiﬂoxacin 94.8 5.2 22.1 77.9 <0.001
doi:10.1371/journal.pone.0145429.t002
Staphylococcus aureus Bacteraemia Trends in Resistance
PLOS ONE | DOI:10.1371/journal.pone.0145429 December 31, 2015 8 / 14
classified as SCCmec type III (41%) typically associated with hospital-acquired infections and
31% of isolates harboured the SCCmec type IV element commonly associated with commu-
nity-acquired infections [19–22]. Our findings have indirect impact on patient care and finally
on public health overall. Distribution of SCCmec, spa and MLST types are important for epide-
miological understanding of transmission of SA isolates by linking resistance patterns with
responding genes. Many data have been published on geographical distribution of MRSA
clones mainly from developed countries; our finding will provide South African dynamics.
However, since we do not have sufficient epidemiological data we cannot make these conclu-
sions. Interestingly, the prevalence of SCCmec type III was higher than SCCmec type IV in
Gauteng and in the Free State. However, in KwaZulu-Natal and in the Western Cape, SCCmec
type IV showed predominance over SCCmec type III. A prevalence of type IV has been seen
previously reported in KwaZuluNatal and the Western Cape [23,24]. Three isolates produced
no SCCmec type. These isolates may express a type not detected with this method or the
SCCmec element may have been excised altogether. Primers used in the reaction amplified 10
loci specific for types I to VI. Due to variability and the SCCmec element being less conserved
in certain regions, detection of regions other than those amplified by our primers may have
been omitted, hence the negative result. Furthermore, excision of SCCmec does occasionally
occur. In the absence of selection pressure SCCmec-excised derivatives could arise in vivo
Fig 4. Association between the most common SCCmec types and clindamycin susceptibility (n = 988).
doi:10.1371/journal.pone.0145429.g004
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where fitness and competition play a role. Moreover, the use of certain antibiotics such as van-
comycin may lead to spontaneous excision of the element [25].
Further molecular characterisation revealed that spa-CC-064 contained isolates displaying
predominantly the SCCmec type IV element whereas spa-CC-037contained isolates that pre-
dominantly displayed SCCmec type III. Both these spa clonal complexes were identified in
Gauteng, Western Cape, KwaZulu-Natal and the Free State. This is in keeping with previous
findings in South Africa [24,26,27].
Fig 5. Distribution of 1003 SCCmec types over the period of three years per province.
doi:10.1371/journal.pone.0145429.g005
Fig 6. Distribution of the most common 393 spa-types per province (total number = 569).
doi:10.1371/journal.pone.0145429.g006
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We further grouped these spa clonal complexes into three major MLST clonal complexes
(CC5, CC8 and CC30). CC8 was the most common and consisted of ST612 and ST239 belong-
ing to spa-CC-064 and spa-CC-037 respectively. Spa-CC-037 also consisted of ST36 (CC30)
and spa-CC-045 consisted of ST5 (CC5). A previous study conducted in South Africa identified
the following major clones that are disseminated globally [27]. These were spa type
t045-SCCmecI-ST5 (CC5), spa type t037-SCCmecIII-ST239 (CC8), spa type t012-SCCmecI-
I-ST36 (CC30) and spa type t064-SCCmecIV-ST612 (CC8). In this study we show similar find-
ings with the exception of spa type t045-SCCmecI-ST5 (CC5) since the SCCmec type identified
in our study was unknown.
The other clone identified in our study was spa type t1257-SCCmecIV-ST612 (CC8). Spa-
types t012 and t037 were grouped together based on spa clonal complex (spa-CC-037) by
BURP analysis. However, these spa types clustered independently of each other based on
SCCmec types (SCCmec types II and III respectively) and MLST (ST36 (CC30) and ST239
(CC8) respectively). This was also seen in a previous study where spa-types t012 and t037
grouped together based on spa clonal complex (spa-CC012) but clustered independently of
each other based on the other molecular typing methods [27]. The presence of these two dis-
tinct MRSA clones is as a result of recombination of a 557kb spa fragment from ST30 (CC30)
into CC8 in the evolution of ST239 (CC8) [28]. Overall, the most common spa-type and ST
observed in our study agrees with previous findings in South Africa. ST612 has to date only
been described in South Africa and Australia [24,26,27].
Due to the population distribution in our country, the majority (59.5%) of analysed isolates
were from Gauteng province followed by the Western Cape (26%), KwaZulu Natal (11%) and
the Free State province (3.5%). The limitation of this study was that MLST was performed on
few isolates, only. It would have been interesting to compare clones obtained in our study to
those observed previously, especially with regards to geographical location. For example, in the
study by Moodley et al., in 2010, F-spaCC-064-SCCmecIV-ST612 was not detected in Gauteng
province from isolates collected in 2005–2006 [27]. However, although we do not have PFGE
results, spaCC-064-SCCmecIV-ST612 was observed in Gauteng in our study approximately 4
Fig 7. Relationship between the most common SCCmec and spa types.
doi:10.1371/journal.pone.0145429.g007
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years later, possibly suggesting the transmission or evolution of clones [27]. In addition, we
only performed MLST on selected isolates collected from each participating province.
Conclusions
MRSA rate is high in South Africa. No resistance to glycopeptides, fluoroquinolones, linezolid,
daptomycin, synercid and fosfomycin was recorded. Majority of the isolates were classified as
SCCmec type III (41%) and type IV (31%), which are typically associated with hospital and
community- acquired infections, respectively. Overall, this study reveals the presence of a vari-
ety of hospital-acquired MRSA clones in South Africa dominance of few clones, spa 037 and
1257. Monitoring trends in resistance and molecular typing is recommended to detect chang-
ing epidemiological trends in AMR patterns of SAB.
Table 3. Genotypes of 569 MRSA isolates.
Spa-CC and Spa-Types MLST SCCmec Type
spa-CC-064 (n = 183)
t008 Unknown
t064 ST612 (CC8) IV
t451 IV
t951 IV










spa-CC-037/012 (n = 311)
t012 ST36 (CC30) Unknown, II, III
t018 Unknown, II
t021 II







spa-CC045 (n = 44)
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